Sorrento Therapeutics

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "the Debtor"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") entered an order approving a $105 million "stalking horse" bid for substantially all of the Debtors' common stock, preferred stock, and warrants (in each case) in Scilex Holding Company ("Scilex" and the "Scilex Stock") to Oramed Pharmaceuticals, Inc. ("Oramed"). The stalking horse agreement with Oramed is subject to an auction and the submission of higher or otherwise better offers.

Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid

Scilex is majority owned by Sorrento, a company I will not invest in. Scilex is a more regular company, doing R&D work, selling drugs and so on. However, it is still entangled with Sorrento, and its stock price movement is too erratic for me.

Scilex: Sorrento's Better Half, Or Its Entangled, Erratic Mover?

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2023) - Gold Hunter Resources Inc. (CSE: HUNT) ("Gold Hunter" or the "Company") is pleased to announce, further to its press release on June 6, 2023, the completion of the sale to Sorrento Resources Ltd. ("Sorrento") of a 100% interest in a portion of its claims comprising the PEG Lithium property, Harmsworth and Tom Joe properties, as well as three properties along the Doucers Valley Fault, all located in the Province of Newfoundland and Labrador (the "Property").

Gold Hunter Resources Completes the Sale of Certain Properties to Sorrento Resources

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Gold Hunter Resources Inc. (CSE: HUNT) ("Gold Hunter" or the "Company") is pleased to announce it has entered into a mineral property purchase agreement dated June 5, 2023, pursuant to which the Company will sell to Sorrento Resources Ltd. (CSE: SRS) ("Sorrento") a 100% interest in a portion of its claims comprising the PEG Lithium property, Harmsworth and Tom Joe properties, as well as three properties along the Doucers Valley Fault, all located in the Province of Newfoundland and Labrador (the "Property").

Gold Hunter Resources Inc. Sells a Portion of Its Newfoundland Projects to Sorrento Resources

CHICAGO, June 05, 2023 (GLOBE NEWSWIRE) -- Shanghai Escugen Biotechnology Co., Ltd. (“Escugen”), a partner of Levena (Suzhou) Biopharma Co., Ltd. (“Levena”), a wholly owned subsidiary of Sorrento Therapeutics, Inc. (Sorrento), today released preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors at the 2023 Annual Meeting of ASCO, the American Society of Clinical Oncology, held June 2-6 in Chicago, IL. ESG401 is an innovative ADC developed by Escugen and Levena. Escugen and Levena Biopharma jointly own the domestic and international patents of this ADC and share global rights for the product. ESG401 is composed of a humanized anti-Trop2 IgG1 monoclonal antibody (mAb) conjugated to a topoisomerase I inhibitor SN38 via a proprietary stable covalent linker with a drug antibody ratio (DAR) of 8. ESG401 has potential differentiated advantages over its competitors in terms of safety, effectiveness and process robustness. Using an innovative, highly stable and cleavable linker, this ADC demonstrated that it releases very little free toxin during circulation, which may reduce off target toxicity in a series of preclinical studies. Additionally, premature release of the mAb may compete for binding sites with the ADC to reduce its efficacy. The ADC highly enriches in tumor tissues and rapidly endocytoses, thereby effectively killing tumor cells and inhibiting tumor growth.

Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the ASCO 2023 Meeting

Any euphoria after the biotech stock's big jump yesterday didn't last long.

Why Sorrento Therapeutics Stock Crashed Today

Sorrento Therapeutics (NASDAQ: SRNE ) stock is trending on social media today, with SRNE stock up 8% at one point this morning. This climb came after shares soared roughly 25% yesterday, although SRNE is now in the red.

The $75 Million Reason Sorrento (SRNE) Stock Is Moving Today

Amyris

AMTD International Inc

Asensus Surgical

LM Funding America

Mobilicom 

Sidus Space

Will penny stock news put these on your buy or sell list this week? The post Penny Stocks To Buy?

Penny Stocks To Buy? 7 To Watch Now After Big News

Ambrx Biopharma Inc

Faraday Future Intelligent Electric

Troika Media Group

Use these tips for staying disciplined when it comes to investing in penny stocks The post How to Stay Disciplined When Investing in Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Stay Disciplined When Investing in Penny Stocks

SAN DIEGO , Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case, which was filed on February 13, 2023.  The financing will provide Sorrento with immediate liquidity so that it can continue operating its business as usual during its chapter 11 case.

Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case

The company is walling off subsidiary Scilex from its bankruptcy proceedings.

Why Shares of Sorrento Therapeutics Are Up Today

Penny stocks with big news in February 2023. Are they the best to buy now?

Best Penny Stocks To Buy Now? 4 With Big News In February

SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company (“Scilex”) previously held by Sorrento.

Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

Bed Bath & Beyond

iBio

How to know when to sell penny stocks The post How to Know When to Sell Penny Stocks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Know When to Sell Penny Stocks

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted an update to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the “Dividend Stock”).

Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)

NexImmune

Use these tips for identifying penny stocks trends in 2023 The post How to Identify Trends With Penny Stocks in 2023  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Identify Trends With Penny Stocks in 2023

SAN DIEGO , Feb. 16, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted approval of Sorrento's employee wages motion and interim approval of its cash management motion, in connection with Sorrento's chapter 11 petition, which was filed on February 13, 2023.  Sorrento expects to seek approval of other customary "first day" motions in the coming days.

Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management Motions

The heavy selling pressure might have exhausted for Sorrento Therapeutics (SRNE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Sorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

SAN DIEGO and PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, together with Sorrento, issued the following statements:

Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today's Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.

Sorrento Therapeutics (NASDAQ: SRNE ) is down by more than 60% today following the company's announcement that it would file for Chapter 11 bankruptcy. Scintilla Pharmaceuticals, a wholly owned subsidiary of Sorrento, will also file for Chapter 11.

5 Investors Betting Big on Sorrento Therapeutics (SRNE) Stock

Sorrento Therapeutics (NASDAQ:SRNE) Inc plunged more than 60% after it was revealed the biopharmaceutical company has filed for Chapter 11 bankruptcy protection as its debts mount amid lawsuits. Sorrento and its wholly-owned subsidiary Scintilla Pharmaceuticals Inc have commenced voluntary bankruptcy proceedings in the US Bankruptcy Court for the Southern District of Texas “to protect the company's business and maximize its value,” according to a document filed with the SEC on Monday.

Sorrento Therapeutics stock plummets more than 60% on news of bankruptcy filing

A famed short-seller already had Sorrento Therapeutics in its sights as far back as 2020. That pressure came to a head Monday.

A biotech company that once claimed to have a 'cure' for COVID-19 just filed for bankruptcy, sending shares plunging 59%

A bankruptcy filing is weighing on the drugmaker's shares today.

Why Sorrento Therapeutics Stock Is Crashing Today

Sorrento Therapeutics (NASDAQ: SRNE ) stock is falling on Monday after the company filed for bankruptcy alongside subsidiary Scintilla Pharmaceuticals. A filing with the U.S. Securities and Exchange Commission (SEC) reveals the bankruptcy filing was made with the United States Bankruptcy Court for the Southern District of Texas.

Why Is Sorrento Therapeutics (SRNE) Stock Down 40% Today?

Vinco Ventures

Lixte Biotech

Here's some tips for sustainably investing in penny stocks The post How to Sustainably Invest in Penny Stocks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Sorrento Therapeutics Stock (SRNE)